Ironwood Pharmaceuticals posted Q2 2026 GAAP net income of $51.29 million, with total revenue up 32.62% to $113.04 million.
Adjusted EBITDA rose 65.75% to $83.04 million, while total costs and expenses fell 15.49% to $33.73 million.
LINZESS U.S. net sales increased 14% to $282.3 million; collaboration revenue climbed 28% to $110 million.
Updated 2026 guidance
Raised 2026 guidance for LINZESS U.S. net sales to $1.15 billion-$1.2 billion, total revenue to $460 million-$485 million, and adjusted EBITDA to more than $310 million.
Cash and capital structure
Cash and cash equivalents ended Q2 at $79.13 million.
Ironwood repaid $200 million of 1.50% convertible senior notes at maturity in June.
IRWD•
